Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

3.569 -0.051 (-1.41%)
Streaming Delayed Price Updated: 12:44 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MannKind Corporation - Common Stock

< Previous 1 2 3 Next >
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
From MannKind
Via GlobeNewswire
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
From MannKind
Via GlobeNewswire
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
From MannKind
Via GlobeNewswire
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
From MannKind
Via GlobeNewswire
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Conference call to provide corporate updates today at 4:30 pm ET 
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
From MannKind
Via GlobeNewswire
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
MannKind Expands Executive Leadership Team
From MannKind
Via GlobeNewswire
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
From MannKind
Via GlobeNewswire
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
From MannKind
Via GlobeNewswire
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
From MannKind
Via GlobeNewswire
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
MannKind to Present at 2024 UBS Healthcare Conference
From MannKind
Via GlobeNewswire
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
From MannKind
Via GlobeNewswire
Lytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor Conference
Phoenix, Arizona and New York, New York--(Newsfile Corp. - September 30, 2024) - Lytham... 
Via Newsfile
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
From MannKind
Via GlobeNewswire
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
From MannKind
Via GlobeNewswire
MannKind to Present at Upcoming Conferences
From MannKind
Via GlobeNewswire
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
From MannKind
Via GlobeNewswire
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 9:00 a.m. (ET) 
From MannKind
Via GlobeNewswire
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
From MannKind
Via GlobeNewswire
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
From MannKind
Via GlobeNewswire
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 5:00 p.m. (ET) 
From MannKind
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.